PARP Inhibitors Market Revenue and Value Chain 2017-2027

PARP Inhibitors Market Industry Trends and Developments 2017 â&#x20AC;&#x201C; 2027 April 2017

About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.

Research Capabilities    

Customized Research Syndicated Research Investment Research

Social Media Research

Customized Research Syndicated Research Investment Research Social Media Research

Sector Coverage    

Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment

   

Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

2

Research Methodology (1/2) Systematic Research Approach 1 Market profiling

2 Formulating discussion guide

3 Developing list of respondents

4

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. PMR formulates a detailed discussion guide to conduct expert and industry interviews PMR develops a list of industry players (manufacturers), distributors, retailers and industry experts

Data collection

PMR conducts interviews with industry experts, industry players, distributors and retailers

Data validation

Data is validated by triangulation method, wherein secondary, primary and PMR analysis contribute to the final data

5 6

Data analysis

Insights

7

Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry PMR delivers industry insights and information in the required format (PDF)

Data Collection

   

Research & Intelligence

Data Filter & Analysis

Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain

Actionable Insights

A Primary Research

     

B SOLUTION     

Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments

Primary Research #    

Linkedin Zoominfo Salesforce Avention

Business Solution

Desk Research

C

Key industry experts Channel study Developments Market dynamics Products Conclusions

Company Analysis

Secondary Research #    

Company websites Company annual reports White papers Financial reports

Paid Publications#    

Factiva GBI Genios Meltwater

# includes sources of databases

3

PARP Inhibitors Market Industry Trends and Developments 2017 â&#x20AC;&#x201C; 2027 Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.

PARP inhibitors Market: Drivers and Restraints PARP inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.

4

PARP Inhibitors Market Industry Trends and Developments 2017 â&#x20AC;&#x201C; 2027 PARP inhibitors market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP inhibitors over the forecast period. In addition, development of PARP inhibitors have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP inhibitors over the forecast period.

PARP inhibitors Market: Segmentation PARP inhibitors market has been segmented on the basis of drug type, indication, distribution channel and Region. Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3197

PARP inhibitors Market: Overview PARP inhibitors market is witnessing significant changes due to increasing opportunity owing to rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis whoâ&#x20AC;&#x2122;s pipeline PARP inhibitors shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP inhibitors. PARP inhibitors market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.

5

PARP Inhibitors Market Industry Trends and Developments 2017 â&#x20AC;&#x201C; 2027 PARP inhibitors Market: Region-wise Outlook Geographically, PARP inhibitors market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP inhibitors market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP inhibitors market by the regions over the forecast period. Asia Pacific PARP inhibitors market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region. Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3197

PARP inhibitors Market: Key Players Some of the players in the global PARP inhibitors market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.

6

To know more about us, please visit our website:

www.futuremarketinsights.com For sales queries or new topics email us on:

sales@futuremarketinsights.com For media queries, contact the press office at press@futuremarketinsights.com For other queries contact:

Harish Tiwari (General Manager & Global Head Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

Thank You Future Market Insights Global & Consulting Private Limited (FMI)

7

Turn static files into dynamic content formats.

Create a flipbook

PARP Inhibitors Market Revenue and Value Chain 2017-2027

Published on Apr 6, 2017

Divakar

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data.